A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer
Author:
Publisher
Elsevier BV
Subject
Multidisciplinary
Reference37 articles.
1. Triple-negative breast cancer: clinical features and patterns of recurrence;Dent;Clin. Cancer Res.,2007
2. BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years;Robertson;Br. J. Cancer,2012
3. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies;Denkert;Lancet,2017
4. Triple-negative breast cancers: unique clinical presentations and outcomes;Billar;Ann. Surg Oncol.,2010
5. Triple-negative breast cancer: an unmet medical need;Hudis;Oncol.,2011
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Exploiting a tumor softening targeted bomb for mechanical gene therapy of chemoresistant Triple-Negative breast cancer;Chemical Engineering Journal;2024-10
2. Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases;Frontiers in Pharmacology;2024-08-19
3. Analysis of the Value of Quantitative Features in Multimodal MRI Images to Construct a Radio-Omics Model for Breast Cancer Diagnosis;Breast Cancer: Targets and Therapy;2024-06
4. Safety and efficacy of anlotinib combined with taxane and lobaplatin in neoadjuvant treatment of clinical stage II/III triple-negative breast cancer in China (the neoALTAL trial): a single-arm, phase 2 trial;eClinicalMedicine;2024-05
5. Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer;Frontiers in Oncology;2024-04-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3